Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD

Contrary to concerns regarding malignancy, venous thromboembolism, and major adverse cardiac events, the use of Janus kinase (JAK) inhibitors is not associated with a significant increase in the overall risk for these conditions in patients with atopic dermatitis (AD),  according to a systematic review and meta-analysis, published in the Journal of the European Academy of Dermatology & Venereology. Recently, […]

Research Seeks to Understand How Climate Change Affects AD, Other Allergic Conditions

Global warming and other environmental changes may be contributing to rising rates of epithelial barrier dysfunction and atopic dermatitis (AD). This is among the main messages from research published in a themed issue of Annals of Allergy, Asthma & Immunology. When the epithelial barrier is disrupted, it facilitates the entry of the external exposome into and […]

FDA Green Lights Leo’s Adbry for Kids With AD

The U.S. Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the first and only FDA-approved biologic that specifically […]

Wound Healing Breakthrough: A New Sustainable Hydrogel Based on Seaweed Exhibits Lower Skin Adhesion, Swelling

A novel, low-cost hydrogel using a component found in seaweed may aid wound healing, according to new research in the International Journal of Biological Macromolecules. The hydrogel was made using alginate, calcium carbonate, and carbonated water. Alginate is a biocompatible substance that can be extracted from beach-cast seaweed that does not adhere strongly to cells or skin tissues.  […]